

Extraordinary Report

March 31, 2023

(TRANSLATION)

Note for readers of this English translation

On March 31, 2023, Chugai Pharmaceutical Co., Ltd. filed its Japanese-language Extraordinary Report (*Rinji Houkokusho*) with the Director-General of the Kanto Financial Bureau in Japan in connection with the Company's shareholders' voting results for proposals acted upon at the 112th Annual General Meeting of Shareholders held on March 30, 2023 pursuant to the Financial Instruments and Exchange Act of Japan. This document is an English translation of the Report.

1. Reason for submitting the Extraordinary Report

Given that resolutions were made for the proposals at the 112th Annual General Meeting of Shareholders (the "Meeting") held on March 30, 2023, Chugai Pharmaceutical Co., Ltd. (the "Company") submits this Extraordinary Report under the provisions of Article 24-5, Paragraph 4, of the Financial Instruments and Exchange Act of Japan and Article 19, Paragraph 2, Item 9-2, of the Cabinet Office Ordinance on Disclosure of Corporate Information, etc. (the "Report").

2. Contents of the Report

(1) Date when the Meeting was held: March 30, 2023

(2) Matters for resolution

First Proposal: Appropriation of Surplus

Year-end dividend

JPY 40 per share of common stock of the Company

Second Proposal: Election of Four (5) Directors

Elect Fumio Tateishi, Hideo Teramoto, Christoph Franz, James H. Sabry, and Teresa A. Graham as Directors of the Company.

Third Proposal: Election of Two (2) Audit & Supervisory Board Members

Elect Shigehiro Yamada and Yumiko Waseda as Audit & Supervisory Board Members of the Company.

(3) Number of voting rights concerning the indication of "for", "against" or "abstention" for each proposal; and Requirements for approving the proposals: Results of the resolutions

Proposal	For	Against	Abstention	Ratio of favorable votes	Results
First Proposal	14,922,146	3,489	0	99.98%	Approved
Second Proposal					
Fumio Tateishi	14,529,273	396,358	0	97.34%	Approved
Hideo Teramoto	14,533,885	391,746	0	97.37%	Approved
Christoph Franz	14,395,571	498,089	31,970	96.45%	Approved
James H. Sabry	14,134,720	758,929	31,970	94.70%	Approved
Teresa A. Graham	14,149,380	744,269	31,970	94.80%	Approved
Third Proposal					
Shigehiro Yamada	14,832,412	93,212	0	99.37%	Approved
Yumiko Waseda	14,922,105	3,523	0	99.98%	Approved

Notes: Requirements for the approval of each proposal are as follows:

- 1) The resolution for the First Proposal must be adopted by the majority of the votes of the shareholders present who are entitled to exercise their voting rights.
- 2) The resolution for the Second and Third Proposals must be adopted by a majority of the votes of the shareholders present at the Meeting where the number of the voting rights of the shareholders present, amounts to one-third (1/3) or more.

(4) Reason why a portion of the voting rights held by the shareholders present at the Meeting held on March 30, 2023 was not added to the number of voting rights

Because in terms of Japanese Companies Act, the required majority approval for each proposal was met by the votes exercised prior to the Meeting held on March 30, 2023, as well as the votes exercised by a portion of shareholders present and confirmed by the Company at the Meeting held on March 30, 2023; and the voting rights of the shareholders present at the Meeting held on March 30, 2023, untraceable with the final decision of "for", "against" or "abstention" as to each proposal were not tallied.